Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, single arm study of ticilimumab in patients with refractory metastatic adenocarcinoma of the colon or rectum

Trial Profile

Phase 2, single arm study of ticilimumab in patients with refractory metastatic adenocarcinoma of the colon or rectum

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2012

At a glance

  • Drugs Tremelimumab (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 06 Jun 2012 Company (AstraZeneca) added as reported by ClinicalTrials.gov.
    • 10 Jul 2008 Status changed from in progress to completed, from clinicaltrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top